Dr Mark Socinski reviews data for first-line dual immunotherapy from the CheckMate-227, CheckMate-9LA, and POSEIDON studies, which demonstrated overall survival advantages in patients with metastatic NSCLC treated with nivolumab plus ipilimumab or durvalumab plus tremelimumab compared with standard-of-care chemotherapy.
